key: cord-0786768-6q6pb0gs
authors: Hu, Qianchao; Zhong, Zibiao; Xiong, Yan; Ye, Shaojun; Wang, Yanfeng; Ye, Qifa
title: Management of immunosuppression in kidney transplant recipients with COVID‐19 pneumonia: A summary of 41 confirmed cases reported worldwide
date: 2020-07-23
journal: Transpl Infect Dis
DOI: 10.1111/tid.13425
sha: 93c420df6e76ad6d506ca54dd52b11aa6a2f48ba
doc_id: 786768
cord_uid: 6q6pb0gs

There is no consensus on immunosuppression management for kidney transplant recipients (KTRs) with SARS‐CoV‐2 pneumonia. Therefore, we conducted a search in English database from October 2019 to July 2020 and extracted data from cases with treatment details worldwide, and total of 41 recipients with a median age of 50 years were enrolled in this study. Most of them were males (75.8%). The most common presenting symptoms were fever (80.5%), cough (63.4%) and fatigue (41.5%). Patients were classified into three catalogs according to severity of pneumonia, 17 (41.5%) were mild, 15 (36.6%) severe and 9 (21.9%) critical disease. Laboratory tests revealed that serum creatinine of critical patients was significantly higher than that of mild or severe patients. 68.3% received oxygen support; all patients received antiviral therapy, 15 (36.6%) recipients were additionally treated with intravenous immunoglobulin and interferon‐α. 19.5% patients maintained immunosuppressive therapy; 36.6% suspended antimetabolite; 43.9% only treated with corticosteroid. 6 (14.6%) patients died (severe: 2, critical: 4); high creatinine with low lymphocyte count was the biggest challenge of immunosuppression management. In all, it is necessary to pay close attention to renal function and lymphocyte count in KTRs infected with COVID‐19, and choose appropriate medication programs according to the specific situations.

With the increasing of cases of COVID-19 pneumonia around the world, reports recently revealed that kidney transplant recipients (KTRs) are more likely to be infected with SARS-CoV-2 under the same exposure conditions because of long-term immunosuppressive therapy. Large scale reports found that the mortality rate of KTRs infected with SARS-CoV-2 was 24%-28%, significantly higher than that of nontransplant patients (1.4%-4.3%) [1, 2] . Many reports showed that patients with COVID-19 were prone to develop lymphocytopenia, and lymphocytopenia was related to the severity of patients [3, 4] . Therefore, reduction or cessation of immunosuppressants seems to contribute to the increase of lymphocytes count in KTRs infected with SARS-CoV-2.

However, reducing the usage of immunosuppressants increased the risk of kidney rejection. So far there is no clear consensus to manage immunosuppressive therapy. Therefore, how to manage immunosuppressive therapy has become a crucial problem in KTRs with In this review, we conducted a search in English database and extracted data from cases with treatment details worldwide, and analyze the relationship between the immunosuppressive regimen and the relevant indicators of KTRs with COVID-19, to provide an effective treatment plan for KTRs with SARS-CoV-2 pneumonia.

We carried out an electronic search in Medline (PubMed interface), Scopus and Web of Science, using the keywords "COVID-19" OR "2019-nCoV" OR "SARS-CoV-2" OR "coronavirus 2019", AND "Transplant" OR "transplantation" OR "transplant recipients"，AND "kidney" OR "renal" ， between October 1, 2019 and July 1, 2020. The reference list of all identified documents was scrutinized with the aim of identifying additional potentially eligible studies. Selection criteria: (1) adult KTRs were diagnosed with SARS-CoV-2 infection; (2) more than 3 months after kidney (single organ) transplantation; (3) specific drug regimens of immunosuppressant; (4) explicit clinical outcome (recovery or death). All references were assessed and selected by two independent reviewers (Qianchao Hu and Zibiao Zhong), and data were extracted from each study. Any disagreements arising during the selection assessment were

This article is protected by copyright. All rights reserved resolved by discussion and consensus. 

A total of 21 reports were screened [5] 

This article is protected by copyright. All rights reserved COVID-19 was classified according to the Guidelines for the Diagnosis and Treatment of COVID-19 (7th) [26] . A total of 41 cases, mild cases was identified in 17 (41.5%), severe cases in 15 (36.6%), and critical cases in 9 (21.9%). There were significant differences between the three groups in terms of age (P = 0.042), while no significant differences in admission time (P = 0.198), and hospital stay (P = 0.788). The laboratory findings showed that there were no significant differences between the three groups in terms of lymphocyte count and C-reactive protein (CRP), while serum creatinine (Cr) in critical cases was significantly higher than mild or severe cases (Cr:

132.55 vs 163.17 vs 244.82, P < 0.024). And there was higher mortality in critical cases than other two subtypes (0 vs 13.3% vs 44.4%). (Table 3 )

All patients received antiviral treatment, and common antiviral drugs were lopinavir/ritonavir, hydroxychloroquine (HCQ), oseltamivir and umifenovir. Some patients additionally treated with intravenous immunoglobulin (IVIg, 34.1%) or interferon-α (INF-α, 9.8%). 68.3% patients received oxygen support. From Table 4 , 35.5% mild cases received oxygen therapy, while in other subtypes the proportion reached to 93.3% and 88.9% respectively.

As for the adjustment of immunosuppression, approach A: maintained on immunosuppression; approach B: only antimetabolites were suspended; approach C: only maintained on corticosteroids. From Table 4 , the application proportion of approach A treatment in different subtypes were 41.2% vs 6.7% vs 0, approach B were 29.4% vs 40% vs 44.4%, approach C were 29.4% vs 53.3% vs 55.6%. The death rate of patient who applied approach A was 0, approach B was 13.3%, approach C was 22.2%. ( Table 4 )

The KTRs with COVID-19 were classified into four types according to Cr and lymphocyte count as Table 5 showed. We first explored differences among those four types in management of immunosuppression. From Table 5 , there was higher mortality in type IV cases than other three types (0 vs 0 vs 0 vs 40%), all the death cases were included into type IV. Moreover, the mortality in type IV cases treated with approach A was 0/0, approach B was 2/6, approach C was 4/9.

This article is protected by copyright. All rights reserved ( Table 5) 

As of July 7, 2020, the total number of confirmed cases of COVID-19 in the world has reached 11.5 million, and the number of daily new cases has not shown a downward trend [27] . For the high infectivity of SARS-Cov-2 and the immunosuppressive state, KTRs were more vulnerable to the influence by COVID-19 than general population under the same exposure conditions. The mortality rate of KTRs with COVID-19 was also significantly higher than that of the general population [1] . Therefore, we collected such literature and carried out statistical analysis trying to find the reasonable basis for management of immunosuppression. This data showed that 41 patients we collected were mainly male (75.6%), with a median age of 50 (IQR: 37, 64) years. The initial symptoms were fever, cough, and fatigue, some patients had digestive system symptoms, like the general population. The severity of patients was divided into mild (41.5%), severe (36.6%), critical (21.9%). The incidence of severe disease was higher than that of the general population [28] . Although the mortality rate was 14.6%, less than 20% -50% in previous reports, it was significantly higher than the general population [29] .

Although there was no specific drug to fight against COVID-19, taking antiviral drugs and general treatment was the best expedient. The main antiviral drugs were lopinavir / ritonavir, HCQ and umifenovir, and some patients were treated additionally with IVIg (34.1%) and INF-α (9.8%).

Previous studies reported that HCQ can effectively fight against SARS-Cov-2 [30] , but in the cases we collected, it did not show significant efficacy. In addition, It was reported that lopinavir / ritonavir could interact with tacrolimus (Tac) [10] . Therefore, we should pay close attention to the blood concentration of Tac when giving lopinavir / ritonavir to KTRs, to prevent the occurrence of adverse events caused by high concentration of Tac. Additionally, those cases we collected showed that using IVIg or INF-a did not improve the prognosis of patients. Oxygen therapy was an important measure to improve the patient's respiratory function. Those cases showed that for mild patients, if they have shortness of breath or dyspnea, nasal cannula should be given; for severe and critical patients, they could be given mechanical ventilation, even extracorporeal

This article is protected by copyright. All rights reserved membrane oxygenation (ECMO).

There were three immunosuppressive regimens for 41 renal transplant recipients. And the adjustment of immunosuppression was divided into 3 approaches. The results showed that the mortality of approach A was 0, the mortality of approach B was 13.3%, and the mortality of approach C was 22.2%. Further analysis found that the patients treated with approach A were mainly mild patients, indicating that approach A was the best choice for mild cases of KTRs, however, it is too hasty to confirm that approach A applies to all patients.

For the management of immunosuppression for severe and critical cases, we divide patients into four types, as shown in Table 5 . Type I and II were mostly mild patients, therefore, approach A was suitable for those two type cases. Notably, type II cases suspended antimetabolites, because antimetabolites can significantly inhibit lymphocyte proliferation, and cessation of antimetabolites would help to alleviate peripheral blood lymphocytes depletion. Previous reports showed that after mycophenolate mofetil (MMF) was stopped, the patient who suffered peripheral blood trisystem reduction was eventually cured [5] .Thus, type II cases should apply approach B when they were also classified into severe patients. Type III and IV were mostly severe and critical patients. The reasons for the deterioration of renal function of type III and IV patients were virus invading and inflammatory response in kidney, which induced lymphocytes to aggregate into renal tissue.

Therefore, we recommend that immunosuppressive therapy should not be changed for the type III patients, because maintaining on immunosuppressive therapy could mitigate excessive inflammatory response. If type III patients continued to deteriorate, they would become type IV.

These patients have respiratory failure, lymphocyte depletion and renal failure at the same time.

The risk of death in type IV patients were very high, this was the biggest challenge for KTRs infected with SARS-Cov-2. In order to maintain the patient's life, mechanical ventilation and renal replacement therapy were important measures. At same time, antimetabolites should be stopped due to lymphocyte depletion; CNI and corticosteroids should be maintained to against the cytokine storm. Previous studies suggested that only application of corticosteroids in type IV cases could not reverse the patient's condition [7, 18] .

We summarized the treatment details of 41 patients in the world, and concluded a set of

This article is protected by copyright. All rights reserved immunosuppression adjustment scheme in this article, hoping to provide adjustment basis for clinicians. However, due to the small number of cases, the author's subjectivity may exist in these reports, which makes our samples biased. Therefore, we call for more clinical reports to focus on the specific adjustment plan of these four types of patients, and finally solve the problem of immunosuppressive adjustment. 

COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter

Covid-19 and Kidney Transplantation

Clinical and immunological features of severe and moderate coronavirus disease 2019

Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia

Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients

Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression

COVID-19 in posttransplant patients-report of 2 cases

COVID-19 in a Kidney Transplant Patient

First case of COVID-19 in a kidney transplant recipient treated with belatacept

Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19)

Accepted Article This article is protected by copyright. All rights reserved

Identification of Kidney Transplant Recipients with Coronavirus Disease

A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China

SARS Cov2 infection in a renal transplanted patients. A case report

COVID-19 in solid organ transplant recipients: a single-center case series from Spain

Case report: A kidney transplant patient with mild COVID-19

Immunosuppressive therapy maintenance in a kidney transplant recipient SARS-CoV-2 pneumonia: a case report

Novel Coronavirus (SARS-CoV-2) Infection in A Renal Transplant Recipient: Case Report

Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China

Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States

Accepted Article This article is protected by copyright. All rights reserved

A Case Report of Oligosymptomatic Kidney Transplant Patients with COVID-19: Do They Pose a Risk to Other Recipients?

Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States

Coronavirus disease 2019 in renal transplant recipients: report of two cases

A Possible Immuno-Neuroendocrine Interface with COVID-19 in a Kidney Transplant Recipient

Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report

SARS-CoV-2 infection in kidney transplant recipients: experience of the italian marche region

New coronavirus pneumonia prevention and control program (7th)

WHO. WHO Coronavirus Disease (COVID-19) Dashboard-Data last updated: 2020/7/7, 2:34pm CEST

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19

HQC and ZZB designed and carried out the research, analyzed the data, and wrote the manuscript. XY, YSJ and WYF provided guidance and revised the manuscript. YQF designed the experiments, provided overall guidance, and helped to write the manuscript.

The authors declare that they have no conflict of interest.

This article is protected by copyright. All rights reserved